SMT201600374B - Modulatori del recettore x del fegato - Google Patents

Modulatori del recettore x del fegato

Info

Publication number: SMT201600374B
Authority: SM; San Marino
Prior art keywords: modulators; liver; receptor
Prior art date: 2012-03-16

Application number

SM201600374T

Other languages

English (en)

Inventor

Chengguo Dong

Yi Fan

Stephen Lotesta

Suresh B Singh

Colin Tice

Yajun Zheng

Linghang Zhuang

Katerina Leftheris

Wei Zhao

Original Assignee

Vitae Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-16

Filing date

2016-10-14

Publication date

2016-11-10

2016-10-14 Application filed by Vitae Pharmaceuticals Inc filed Critical Vitae Pharmaceuticals Inc

2016-11-10 Publication of SMT201600374B publication Critical patent/SMT201600374B/it

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Obesity (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Child & Adolescent Psychology (AREA)
Ophthalmology & Optometry (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)

SM201600374T 2012-03-16 2016-10-14 Modulatori del recettore x del fegato SMT201600374B (it)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261612051P	2012-03-16	2012-03-16
PCT/US2013/031242 WO2013138565A1 (en)	2012-03-16	2013-03-14	Liver x receptor modulators

Publications (1)

Publication Number	Publication Date
SMT201600374B true SMT201600374B (it)	2016-11-10

Family

ID=47997957

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM201600374T SMT201600374B (it)	2012-03-16	2016-10-14	Modulatori del recettore x del fegato

Country Status (27)

Country	Link
US (4)	US9006244B2 (it)
EP (1)	EP2825541B1 (it)
JP (3)	JP6114814B2 (it)
KR (1)	KR102069912B1 (it)
CN (1)	CN104203951B (it)
AU (1)	AU2013232066B2 (it)
CA (1)	CA2866218C (it)
CY (1)	CY1118318T1 (it)
DK (1)	DK2825541T3 (it)
EA (1)	EA026907B1 (it)
ES (1)	ES2598653T3 (it)
HR (1)	HRP20161196T1 (it)
HU (1)	HUE029402T2 (it)
IL (1)	IL234265B (it)
IN (1)	IN2014DN07636A (it)
LT (1)	LT2825541T (it)
ME (1)	ME02534B (it)
MX (1)	MX354818B (it)
NZ (1)	NZ629122A (it)
PL (1)	PL2825541T3 (it)
PT (1)	PT2825541T (it)
RS (1)	RS55166B1 (it)
SG (1)	SG11201405328SA (it)
SI (1)	SI2825541T1 (it)
SM (1)	SMT201600374B (it)
WO (1)	WO2013138565A1 (it)
ZA (1)	ZA201406326B (it)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104203950B (zh) *	2012-03-16	2016-08-24	生命医药公司	肝x受体调节剂
HUE029402T2 (en) *	2012-03-16	2017-02-28	Vitae Pharmaceuticals Inc	Liver X receptor modulators
EP3091970B1 (en)	2014-01-10	2020-10-28	Rgenix, Inc.	Lxr agonists and uses thereof
WO2015195922A1 (en) *	2014-06-19	2015-12-23	Vitae Pharmaceuticals, Inc.	Compounds for use in treating acute coronary syndrome and related conditions
BR112017002260A2 (pt) *	2014-08-07	2017-11-21	Vitae Pharmaceuticals Inc	derivados de piperazina como moduladores do receptor x do fígado
US20190125745A1 (en) *	2014-12-17	2019-05-02	Rgenix, Inc.	Treatment and diagnosis of cancer
CN105017262B (zh) *	2015-07-07	2017-05-03	广东也乐新材料制造有限公司	一种醛基取代多环杂芳烃化合物的合成方法
CN105288658B (zh) *	2015-10-30	2018-08-28	中国人民解放军第三军医大学	miR-18a-5p抑制剂在制备防治骨质疏松药物中的应用
CN109069461A (zh)	2016-01-11	2018-12-21	洛克菲勒大学	与髓源性抑制细胞相关的病症的治疗方法
EP3713575A4 (en)	2017-11-21	2021-08-25	Rgenix, Inc.	POLYMORPHS AND THEIR USES
HUE067466T2 (hu)	2019-12-13	2024-10-28	Inspirna Inc	Fémsók és alkalmazásuk

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4748247A (en)	1986-10-21	1988-05-31	American Home Products Corporation	2-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]alkyl]alkyl]pyrido- and pyrazino-indole-1,3-dione derivatives as histamine H1 antagonists
JPH05503518A (ja)	1990-01-22	1993-06-10	イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー	除草性スルホニル尿素
EP0572863A1 (de)	1992-06-05	1993-12-08	F. Hoffmann-La Roche Ag	ZNS Pyrazinoindole
JP3998261B2 (ja)	1993-12-23	2007-10-24	イーライ・リリー・アンド・カンパニー	プロテインキナーゼｃ阻害剤
US5545636A (en)	1993-12-23	1996-08-13	Eli Lilly And Company	Protein kinase C inhibitors
WO1996012721A1 (en)	1994-10-20	1996-05-02	American Home Products Corporation	Indole derivatives useful as serotonergic agents
US5854245A (en)	1996-06-28	1998-12-29	Merck & Co., Inc.	Fibrinogen receptor antagonists
JP2000513375A (ja)	1996-06-28	2000-10-10	メルクエンドカンパニーインコーポレーテッド	フィブリノーゲンレセプター拮抗薬プロドラッグ
JP2000514427A (ja)	1996-06-28	2000-10-31	メルクエンドカンパニーインコーポレーテッド	フィブリノーゲンレセプター拮抗薬プロドラッグ
JP2000514061A (ja)	1996-06-28	2000-10-24	メルクエンドカンパニーインコーポレーテッド	フィブリノーゲン受容体拮抗物質
US6177440B1 (en)	1996-10-30	2001-01-23	Eli Lilly And Company	Substituted tricyclics
FR2761070B1 (fr)	1997-03-20	1999-04-23	Synthelabo	Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
FR2761073B1 (fr) *	1997-03-20	1999-04-23	Synthelabo	Derives de pyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
DE19802235A1 (de)	1998-01-22	1999-07-29	Bayer Ag	Mit tricyclischen Indolen substituierte Oxazolidinone
IL129484A0 (en)	1998-04-17	2000-02-29	Lilly Co Eli	Substituted tricyclics
ATE289593T1 (de)	1999-05-06	2005-03-15	Neurogen Corp	Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden
US7037916B2 (en)	1999-07-15	2006-05-02	Pharmacopeia Drug Discovery, Inc.	Pyrimidine derivatives as IL-8 receptor antagonists
IT1313593B1 (it)	1999-08-03	2002-09-09	Novuspharma Spa	Derivati di 1,2-diidro-1-oxo-pirazino 1,2-a indolo.
WO2001030331A2 (en)	1999-10-22	2001-05-03	Eli Lilly And Company	Therapeutic compositions including protein kinase c inhibitors
AU779855B2 (en)	2000-01-06	2005-02-17	Axys Pharmaceuticals, Inc.	Novel compounds and compositions as protease inhibitors
DE60113865T2 (de)	2000-07-31	2006-07-20	Vernalis Research Ltd., Winnersh	Piperazin derivate
CA2432122A1 (en)	2000-12-20	2002-08-01	Bristol-Myers Squibb Pharma Company	Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands
GB0106177D0 (en) *	2001-03-13	2001-05-02	Hoffmann La Roche	Piperazine derivatives
FR2829766A1 (fr)	2001-09-14	2003-03-21	Lipha	Derives d'oxamates comportant un heterocycle azote diversement substitue
NZ533649A (en)	2001-12-21	2006-01-27	King Pharmaceuticals Res & Dev	Tyrosyl derivatives and their use as P2X7 receptor modulators
US7919497B2 (en)	2002-08-02	2011-04-05	Nereus Pharmaceuticals, Inc.	Analogs of dehydrophenylahistins and their therapeutic use
DE10320780A1 (de)	2003-05-09	2005-01-20	Bayer Healthcare Ag	Heterocyclyl-substituierte Dihydrochinazoline
US7994196B2 (en)	2004-02-12	2011-08-09	Mitsubishi Tanabe Pharma Corporation	Indazole compound and pharmaceutical use thereof
AU2005230399B2 (en)	2004-04-08	2009-07-09	Novartis Ag	Protein kinase C inhibitors for the treatment of autoimmune diseases and of transplant rejection
RU2266906C1 (ru)	2004-04-29	2005-12-27	Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия")	Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека
ITMI20040874A1 (it)	2004-04-30	2004-07-30	Ist Naz Stud Cura Dei Tumori	Derivati indolici ed azaindolici con azione antitumorale
WO2005113526A2 (en)	2004-05-21	2005-12-01	Pfizer Products Inc.	Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
ES2338139T3 (es)	2004-12-15	2010-05-04	F. Hoffmann-La Roche Ag	Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador de la glicina i (glyt-1) para el tratamiento de la enfermedad de alzheimer.
CA2593266A1 (en)	2005-01-03	2006-07-13	Universita Degli Studi Di Siena	Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
US7790712B2 (en)	2005-03-17	2010-09-07	Boehringer Ingelheim Pharmaceutical, Inc.	Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
WO2006106423A2 (en)	2005-04-07	2006-10-12	Pfizer Inc.	Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
PL1904477T3 (pl)	2005-07-14	2009-07-31	Hoffmann La Roche	Pochodne indolo-3-karbonylo-spiro-piperydyny jako antagoniści receptora V1a
EP1926724A1 (en)	2005-09-21	2008-06-04	Nereus Pharmaceuticals, Inc.	Analogs of dehydrophenylahistins and their therapeutic use
EP1779848A1 (en)	2005-10-28	2007-05-02	Nikem Research S.R.L.	V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
JP2007137810A (ja) *	2005-11-17	2007-06-07	Sankyo Co Ltd	インドール化合物を含有する医薬
DE602006010433D1 (de)	2005-12-09	2009-12-24	Hoffmann La Roche	Für die behandlung von obesitas geeignete tricyclische amidderivate
US7351706B2 (en)	2006-01-05	2008-04-01	Hoffmann-La Roche Inc.	Indol-3-yl-carbonyl-spiro-piperidine derivatives
FR2897061B1 (fr) *	2006-02-03	2010-09-03	Sanofi Aventis	Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
RU2318818C1 (ru)	2006-04-12	2008-03-10	Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия"	Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
US8129527B2 (en)	2006-11-03	2012-03-06	Nereus Pharmacuticals, Inc.	Analogs of dehydrophenylahistins and their therapeutic use
WO2008122115A1 (en)	2007-04-09	2008-10-16	Methylgene Inc.	Inhibitors of histone deacetylase
KR20100040872A (ko)	2007-06-25	2010-04-21	뉴로젠 코포레이션	피페라지닐 옥소알킬 테트라하이드로-베타-카르볼린 및 이의 관련 유사체
WO2009042092A1 (en)	2007-09-25	2009-04-02	Merck & Co., Inc.	2-aryl or heteroaryl indole derivatives
CN101456863B (zh) *	2007-12-14	2012-04-25	华北制药集团新药研究开发有限责任公司	Lxr激动剂及其制备方法和用途
WO2009086129A1 (en) *	2007-12-21	2009-07-09	Wyeth	Pyrazolo [1,5-a] pyrimidine compounds
UY31604A1 (es)	2008-01-22	2009-08-31		Compuestos tricíclicos y uso de los mismos
WO2009097515A2 (en)	2008-01-30	2009-08-06	Wyeth	[a]-fused indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US20100137320A1 (en)	2008-02-29	2010-06-03	Schering Corporation	Gamma secretase modulators
EP2254886B1 (en)	2008-03-28	2016-05-25	Nerviano Medical Sciences S.r.l.	3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
TW201031665A (en)	2009-02-04	2010-09-01	Gruenenthal Gmbh	Substituted indole-compound
CA2764622A1 (en)	2009-06-08	2010-12-16	Stefan Schunk	Substituted benzimidazoles, benzothiazoles and benzoxazoles
WO2011005295A1 (en)	2009-06-24	2011-01-13	Arena Pharmaceuticals, Inc.	Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
EP2475664A2 (en)	2009-09-11	2012-07-18	Sunovion Pharmaceuticals Inc.	Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2011071725A1 (en)	2009-12-07	2011-06-16	Boehringer Ingelheim International Gmbh	Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
WO2011109237A2 (en)	2010-03-02	2011-09-09	Emory University	Uses of noscapine and derivatives in subjects diagnosed with fap
US8654867B2 (en) *	2011-12-07	2014-02-18	Texas Instruments Incorporated	Transformer power combiner with filter response
HUE029402T2 (en) *	2012-03-16	2017-02-28	Vitae Pharmaceuticals Inc	Liver X receptor modulators
CN104203950B (zh) *	2012-03-16	2016-08-24	生命医药公司	肝x受体调节剂

2013
- 2013-03-14 HU HUE13712102A patent/HUE029402T2/en unknown
- 2013-03-14 LT LTEP13712102.6T patent/LT2825541T/lt unknown
- 2013-03-14 HR HRP20161196TT patent/HRP20161196T1/hr unknown
- 2013-03-14 CA CA2866218A patent/CA2866218C/en not_active Expired - Fee Related
- 2013-03-14 EA EA201491609A patent/EA026907B1/ru unknown
- 2013-03-14 RS RS20160785A patent/RS55166B1/sr unknown
- 2013-03-14 US US14/385,688 patent/US9006244B2/en active Active
- 2013-03-14 CN CN201380014354.5A patent/CN104203951B/zh not_active Expired - Fee Related
- 2013-03-14 PT PT137121026T patent/PT2825541T/pt unknown
- 2013-03-14 MX MX2014011103A patent/MX354818B/es active IP Right Grant
- 2013-03-14 NZ NZ629122A patent/NZ629122A/en not_active IP Right Cessation
- 2013-03-14 EP EP13712102.6A patent/EP2825541B1/en active Active
- 2013-03-14 JP JP2015500602A patent/JP6114814B2/ja not_active Expired - Fee Related
- 2013-03-14 DK DK13712102.6T patent/DK2825541T3/en active
- 2013-03-14 PL PL13712102.6T patent/PL2825541T3/pl unknown
- 2013-03-14 ME MEP-2016-211A patent/ME02534B/me unknown
- 2013-03-14 AU AU2013232066A patent/AU2013232066B2/en not_active Ceased
- 2013-03-14 IN IN7636DEN2014 patent/IN2014DN07636A/en unknown
- 2013-03-14 SI SI201330303A patent/SI2825541T1/sl unknown
- 2013-03-14 ES ES13712102.6T patent/ES2598653T3/es active Active
- 2013-03-14 KR KR1020147028754A patent/KR102069912B1/ko not_active Expired - Fee Related
- 2013-03-14 SG SG11201405328SA patent/SG11201405328SA/en unknown
- 2013-03-14 WO PCT/US2013/031242 patent/WO2013138565A1/en not_active Ceased
2014
- 2014-08-24 IL IL234265A patent/IL234265B/en active IP Right Grant
- 2014-08-27 ZA ZA201406326A patent/ZA201406326B/en unknown
- 2014-11-19 US US14/547,804 patent/US9006245B2/en active Active
2015
- 2015-03-13 US US14/657,179 patent/US9388190B2/en active Active
2016
- 2016-06-15 US US15/182,749 patent/US9814715B2/en active Active
- 2016-09-22 CY CY20161100948T patent/CY1118318T1/el unknown
- 2016-10-14 SM SM201600374T patent/SMT201600374B/it unknown
2017
- 2017-03-14 JP JP2017048432A patent/JP2017128588A/ja active Pending
2018
- 2018-09-14 JP JP2018172260A patent/JP2019023196A/ja active Pending

Also Published As

Publication number	Publication date
EP2825541A1 (en)	2015-01-21
ES2598653T3 (es)	2017-01-30
IN2014DN07636A (it)	2015-05-15
AU2013232066A1 (en)	2014-09-11
CN104203951B (zh)	2016-11-02
HK1206333A1 (en)	2016-01-08
US20150080406A1 (en)	2015-03-19
PL2825541T3 (pl)	2016-12-30
ZA201406326B (en)	2019-11-27
US20150246924A1 (en)	2015-09-03
IL234265B (en)	2020-06-30
JP2017128588A (ja)	2017-07-27
CN104203951A (zh)	2014-12-10
MX354818B (es)	2018-03-21
CA2866218A1 (en)	2013-09-19
AU2013232066B2 (en)	2017-07-06
RS55166B1 (sr)	2017-01-31
KR102069912B1 (ko)	2020-01-23
HUE029402T2 (en)	2017-02-28
DK2825541T3 (en)	2016-10-03
JP2015510892A (ja)	2015-04-13
PT2825541T (pt)	2016-09-28
JP2019023196A (ja)	2019-02-14
LT2825541T (lt)	2016-12-27
HRP20161196T1 (hr)	2016-11-04
US20150051214A1 (en)	2015-02-19
US9814715B2 (en)	2017-11-14
MX2014011103A (es)	2014-12-05
WO2013138565A1 (en)	2013-09-19
EA201491609A1 (ru)	2014-12-30
US9006245B2 (en)	2015-04-14
SI2825541T1 (sl)	2016-10-28
EA026907B1 (ru)	2017-05-31
KR20140139555A (ko)	2014-12-05
CY1118318T1 (el)	2017-06-28
SG11201405328SA (en)	2014-11-27
ME02534B (me)	2017-02-20
NZ629122A (en)	2016-04-29
US9388190B2 (en)	2016-07-12
CA2866218C (en)	2020-06-09
US9006244B2 (en)	2015-04-14
EP2825541B1 (en)	2016-06-22
JP6114814B2 (ja)	2017-04-12
US20170136017A1 (en)	2017-05-18

Publication	Publication Date	Title
NL301268I2 (nl)	2024-05-15	rozanolixizumab
SMT201700009B (it)	2017-03-08	Modulatori del recettore x del fegato
DK3848027T3 (da)	2023-05-01	Octahydro-kondenserede azadecalinglucocorticoidreceptormodulatorer
ME03081B (me)	2019-01-20	Modulatora receptora androgena patentni zahtevi
EP2838564A4 (en)	2015-12-02	HIGH-BRANCHED ALPHA-D-GLUCANE
DK2863961T3 (da)	2019-01-02	Hæmostatiske indretninger
LT3091141T (lt)	2018-08-10	Lengvesnės grindų plokštės iš mažiau medžiagų
PT2878018T (pt)	2018-02-22	Resumo
DK2859055T3 (da)	2021-02-22	Polymercoatings
EP2902071A4 (en)	2016-06-08	INTERCONNECTS
DK2825087T3 (da)	2019-05-13	Otoscanner
PT2819623T (pt)	2018-01-19	Resumo
DK2839013T3 (da)	2020-09-14	Ikke-disruptiv-gen-targetering
DK2684610T4 (da)	2021-11-08	Bruser
SMT201600374B (it)	2016-11-10	Modulatori del recettore x del fegato
DE112012006109A5 (de)	2014-12-18	Okklusionsschienenanordnung
CO6990736A2 (es)	2014-07-10	Pirrolidina-2-carboxamidas sustituídas
DK2854722T3 (da)	2020-08-24	Stomipose
BR112014032798A2 (pt)	2017-06-27	composição
EP2999699A4 (en)	2016-10-26	PURINE DIONES AS MODULATORS OF THE WNT PATH
EP2803885A4 (en)	2015-11-11	MIXER
PT2831109T (pt)	2018-02-07	Resumo
FR2998638B1 (fr)	2016-04-15	Raccord
DK2825157T3 (da)	2019-01-02	Aminosyrelipider
EP2911666A4 (en)	2016-10-12	MODULATORS OF A RESISTANT ANDROGEN RECEPTOR